MYCi361 NUCC-0196361|cas:2289690-31-7|西域试剂

MYCi361 NUCC-0196361,99.85%

产品编号：Bellancom-129600| CAS NO：2289690-31-7| 分子式：C₂₆H₁₆ClF₉N₂O₂| 分子量：594.86

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-129600	￥3500.00	杭州北京（现货）
Bellancom-129600	￥5500.00	杭州北京（现货）
Bellancom-129600	￥9900.00	杭州北京（现货）
Bellancom-129600	￥0.00	杭州北京（现货）
Bellancom-129600	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

MYCi361 NUCC-0196361

产品介绍

MYCi361 (NUCC-0196361) 是一种 MYC 抑制剂，其与 MYC 结合的 K_d 为 3.2 μM。MYCi361 (NUCC-0196361) 抑制肿瘤生长并增强 anti-PD1 免疫疗法。

生物活性

MYCi361 (NUCC-0196361) is a MYC inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.

体外研究

MYCi361 inhibits the viability of MYC-dependent cancer cells including prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2) with low-micromolar IC₅₀ values.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	The prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2).
Concentration:	1.4-5.0 μM
Incubation Time:	5 days
Result:	IC₅₀s of 2.9, 1.4, 1.6, 2.6, 5.0, 2.1, and 4.9 μM for prostate cancer (MycCaP, LNCaP, and PC3), leukemia (MV4-11), lymphoma (HL-60 and P493-6), and neuroblastoma (SK-N-B2), respectively.

体内研究
(In Vivo)

MYCi361 inhibits MYC-dependent tumor growth in vivo. MYCi361 treatment (100 mg/kg/day for 2 days; then 70 mg/kg/day for 9 days) induces tumor regression in FVB or NSG male mice.
MYCi361 has moderate terminal elimination half-life of 44 and 20 h for intraperitoneal (i.p.) or oral (p.o.) dosing in mice, respectively.
MYCi361 suppresses tumor growth in mice, increases tumor immune cell infiltration, upregulates PD-L1 on tumors, and sensitizes tumors to anti-PD1 immunotherapy. However, MYCi361 demonstrates a narrow therapeutic index. An improved analog, MYCi975 shows better tolerability.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors
Dosage:	50 mg/kg and 70 mg/kg
Administration:	Treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days
Result:	Induced tumor regression.

Animal Model:	C57BL/6 mice
Dosage:	50 mg/kg (Pharmacokinetic analysis)
Administration:	Treated p.o. or i.p.; 24 hours
Result:	Intraperitoneal (i.p.) or oral (p.o.) dosing in mice indicated plasma half-lives of 44 and 20 h, respectively, with maximum plasma concentrations (C_max) of 27,200 ng/mL (46 μM) i.p. and 13,867 ng/mL (23 μM) p.o..

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors
Dosage:	50 mg/kg and 70 mg/kg
Administration:	Treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days
Result:	Induced tumor regression.

Animal Model:	C57BL/6 mice
Dosage:	50 mg/kg (Pharmacokinetic analysis)
Administration:	Treated p.o. or i.p.; 24 hours
Result:	Intraperitoneal (i.p.) or oral (p.o.) dosing in mice indicated plasma half-lives of 44 and 20 h, respectively, with maximum plasma concentrations (C_max) of 27,200 ng/mL (46 μM) i.p. and 13,867 ng/mL (23 μM) p.o..

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	FVB or NSG male mice of 6-8 weeks of age and 25 g bearing established MycCaP tumors
Dosage:	50 mg/kg and 70 mg/kg
Administration:	Treatment i.p. initially at 50 mg/kg twice daily for 2 days, then 70 mg/kg/day for 9 days
Result:	Induced tumor regression.

Animal Model:	C57BL/6 mice
Dosage:	50 mg/kg (Pharmacokinetic analysis)
Administration:	Treated p.o. or i.p.; 24 hours
Result:	Intraperitoneal (i.p.) or oral (p.o.) dosing in mice indicated plasma half-lives of 44 and 20 h, respectively, with maximum plasma concentrations (C_max) of 27,200 ng/mL (46 μM) i.p. and 13,867 ng/mL (23 μM) p.o..

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (168.11 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.6811 mL	8.4053 mL	16.8107 mL
5 mM	0.3362 mL	1.6811 mL	3.3621 mL
10 mM	0.1681 mL	0.8405 mL	1.6811 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (3.50 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (3.50 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。